Report of Foreign Issuer (6-k)
January 03 2018 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of January 2018
001-36345
(Commission File Number)
GALMED PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in
its charter)
16 Tiomkin St.
Tel Aviv 6578317, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover
Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Galmed Pharmaceuticals Ltd. has posted
to its website an updated corporate presentation. A copy of the presentation is furnished with this Report of Foreign Private Issuer
on Form 6-K as Exhibit 99.1 and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Galmed Pharmaceuticals Ltd.
|
|
|
|
Date: January 3, 2018
|
By:
|
/s/ Allen Baharaff
|
|
|
Allen Baharaff
|
|
|
President and Chief Executive Officer
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Corporate presentation January
2018
|
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Apr 2023 to Apr 2024